Skip to main content
Fig. 1 | Biology Direct

Fig. 1

From: PLAU promotes growth and attenuates cisplatin chemosensitivity in ARID1A-depleted non-small cell lung cancer through interaction with TM4SF1

Fig. 1

Upregulation of PLAU in ARID1A-deficient NSCLC cells. (A) Venn diagram of differentially expressed genes in GSE218822, GSE180468, and GSE132359. (B) Overall survival curves comparing the high and low expression of PLAU in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) from Kaplan-Meier plotter. HR: hazard ratio. (C) Negative correlation between PLAU and ARID1A in LUAD and LUSC based on the ENCORI database. (D) Relative ARID1A protein levels determined by Western blot analysis in NSCLC cells transfected with 2 shRNAs targeting ARID1A. (E) Effects of 2 shRNAs targeting ARID1A on the expression of indicated genes. *P < 0.05. ns indicates no significance. (F,G) ChIP assay. Chromatin from A549 (F) and H1299 (G) cells transfected with indicated shRNAs was immunoprecipitated with anti-ARID1A antibody or control IgG. DNA fragments of the promoter of PLAU were quantitated by real-time PCR analysis. (H, I) Measurement of the PLAU promoter-driven luciferase activities in A549 (H) and H1299 (I) cells transfected with indicated shRNAs. *P < 0.05 relative to the shCtrl group

Back to article page

Biology Direct

ISSN: 1745-6150

Contact us